Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 5, 2011, Pages 1343-1349

  Parker, Alexander S ^a   Heckman, Michael G ^a   Sheinin, Yuri ^b   Wu, Kevin J ^a   Hilton, Tracy W ^a   Diehl, Nancy N ^a   Pisansky, Thomas M ^b   Schild, Steven E ^c   Kwon, Eugene D ^b   Buskirk, Steven J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Biochemical recurrence; Prostate cancer; Salvage radiation therapy; Tumor biomarker

Indexed keywords

ADJUVANT THERAPY; BIOCHEMICAL RECURRENCE; CONFIDENCE INTERVAL; COVARIATES; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCERS; RADIATION THERAPY; RELATIVE RISKS; SALVAGE RADIATION THERAPY; VARIABLE ANALYSIS; VISUAL ASSESSMENTS;

DISEASES; MONOCLONAL ANTIBODIES; OPTIMIZATION; TUMORS;

RADIOTHERAPY;

MEMBRANE PROTEIN; PROTEIN B7 H3; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECURRENCE RISK; RECURRENT CANCER; RISK FACTOR; SALVAGE THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC; SALVAGE THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952703623     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.01.061     Document Type: Article

References (27)

1. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632-1642. (Pubitemid 30366704)
2. Pound CR, Partin AW, Eisneberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999;281:1591-1597. (Pubitemid 29211767)
3. Roberts SG, Blute ML, Bergstralh EJ, et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-581.
4. Patel A, Dorey F, Franklin J, et al. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997;158:1441-1445. (Pubitemid 27391215)
5. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. J Am Med Assoc 2008;299:2760-2769. (Pubitemid 351846851)
6. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow-up of a randomized clinical trial. J Urol 2009;181:956-962.
7. Leventis AK, Shariat SF, Kattan MW, et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001;19:1030-1039. (Pubitemid 32176278)
8. Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003;21:483-489. (Pubitemid 46606478)
9. Pisansky TM, Kozelsky TF, Myers RP, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000;163:845-850. (Pubitemid 30091629)
10. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. J Am Med Assoc 2004;291:1325-1332. (Pubitemid 38541647)
11. Buskirk SJ, Pisansky TM, Schild SE, et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: Evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006;176:985-990. (Pubitemid 44160708)
12. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-548.
13. Zang X, Loke P, Kim J, et al. B7x: A widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 2003;100:10388-10392. (Pubitemid 37071888)
14. Zou W. Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nature Rev Immunol 2008;8:467-477. (Pubitemid 351733418)
15. Seliger B, Marincola FM, Ferrone S, et al. The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008;14:550-559.
16. Krambeck AE, Thompson RH, Dong H, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006;103:10391-10396. (Pubitemid 44051177)
17. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 2005;104:2084-2091. (Pubitemid 41579953)
18. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004;101:17174-17179. (Pubitemid 39627793)
19. Sun Y, Wang Y, Zhao J, Gu M, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006;53:143-151. (Pubitemid 43994236)
20. Zang X, Thompson RH, Al-Ahmadie HA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad SciU S A 2007;104:19458-19463.
21. Roth TJ, Sheinin Y, Lohse CM, et al. B7-H3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy. Cancer Res 2007;67:7893-7900. (Pubitemid 47281385)
22. Harrell FE, LeeKL,MarkDB.Multivariate prognosticmodels: Issues in developingmodels, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
23. Blute ML, Bergstralh EJ, Iocca A, et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:115-119.
24. Chapoval AI, Ni J, Lau JS, et al. B7-H3: A costimulatory molecule for T cell activation and IFN-γ production. Nat Immunol 2001;2:269-274.
25. Wang LQ, Fraser CC, Kikly K, et al. B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol 2005;35:428-438. (Pubitemid 40331320)
26. Suh WK, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003;4:899-906. (Pubitemid 37098661)
27. Prasad DVR, Nguyen T, Li ZX, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol 2004;173:2500-2506. (Pubitemid 39063108)